ONCOLife Issues
Featured Articles
Trending Articles
FDA Approves Durvalumab as First Perioperative Immunotherapy for GEJ Cancers
FDA & EMA | 26 November 2025
FDA Approves Keytruda–Padcev Combo as First Perioperative Treatment for Bladder Cancer
FDA & EMA | 24 November 2025
Sevabertinib Wins FDA Approval with Strong Responses in HER2+ NSC Lung Cancer
FDA & EMA | 20 November 2025
FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma
FDA & EMA | 19 November 2025
FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia
FDA & EMA | 14 November 2025
Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer
ONCOLife | 5 November 2025
Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer
ONCOLife | 6 November 2025
Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad
Pharma | 11 November 2025
Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer
ONCOLife | 3 November 2025
DeLLphi-303: Tarlatamab Plus Chemo Achieves 71% Response in ES Small-Cell Lung Cancer
ONCOLife | 4 November 2025
Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer
ONCOLife | 24 October 2025
Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer
ONCOLife | 21 October 2025
Molecular Trojan Horse: Peptide Nanotubes Offer a Path to Defeat Drug-Resistant Tumors
ONCOLife
13 October 2025
Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers
ONCOLife
12 October 2025
In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach
Pharma
10 October 2025
FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma
FDA & EMA
9 October 2025
Datroway Improves Survival in First-Line Treatment of Metastatic Triple- Breast Cancer
ONCOLife
6 October 2025
FDA Approves Tecentriq–Zepzelca Combo as FL Maintenance Therapy for ES-SC Lung Cancer
FDA & EMA
3 October 2025
Dr. Eleni Lagkadinou Discusses How AbbVie Is Advancing Targeted Innovation for HT Cancers
ONCOLife
1 October 2025
FDA Approves Imlunestrant for ESR1-Mutated Metastatic Breast Cancer
FDA & EMA
27 September 2025
DESTINY-Breast05: Enhertu Outperforms T-DM1 in High-Risk HER2+ Early Breast Cancer
FDA & EMA
1 October 2025
Giredestrant Plus Everolimus Improves PF Survival in ER+ Advanced Breast Cancer
ONCOLife
26 September 2025
The V Foundation and CVC Collaborate to Advance Breast Cancer Vaccine Research
ONCOLife
12 September 2025